세계의 타겟 시퀀싱 시장 : 제품 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Targeted Sequencing Market was valued at USD 6.23 billion in 2023, expected to reach USD 7.60 billion in 2024, and is projected to grow at a CAGR of 20.30%, to USD 22.73 billion by 2030.

Targeted sequencing is a technique used to analyze specific areas of the genome rather than the entire genetic sequence, making it both time-efficient and cost-effective by focusing on regions of interest that are pertinent to particular diseases or conditions. Its necessity stems from its ability to provide comprehensive insights into genetic mutations, facilitating advancements in personalized medicine, cancer research, and rare disease diagnosis. Applications extend into clinical diagnosis, drug development, agrigenomics, and molecular biology research, with end-use across healthcare, biotechnology, and agricultural sectors. The market is buoyed by factors such as technological advancements in sequencing methods, increased genetic research funding, and the growing prevalence of genetic disorders. Adoption of targeted sequencing is expected to rise as the demand for personalized medicine and companion diagnostics increases. Recent opportunities arise from advancements in bioinformatics tools and the decreasing cost of sequencing technologies. Companies can capitalize on these by investing in innovative technologies that increase efficiency and accuracy, as well as expanding their services to emerging markets where genetic research is gaining momentum.

However, market growth faces limitations such as high initial costs, complex regulatory approval processes, and data interpretation challenges. Additionally, a lack of skilled professionals for data analysis and an ethical debate surrounding genetic privacy may pose hurdles. To overcome these, businesses should focus on developing user-friendly, automated platforms and foster collaborations with educational institutions for workforce training.

Innovation opportunities lie in enhancing sequencing accuracy and speed, integrating AI for better data analysis, and exploring new applications of targeted sequencing in other fields like zoology and anthropology. Considering the market's nature, which is fast-paced and heavily reliant on technological advances, industry stakeholders should emphasize research partnerships and continuous development to maintain a competitive edge in this dynamic sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Targeted Sequencing Market

The Targeted Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Extensive adoption of targeted sequencing technologies in clinical diagnostics due to rapid result time and higher accuracy
  • Emerging adoption in the agriculture sector to analyze the genetic potential of plants
  • Increased application of targeted sequencing for precision medicines
• Market Restraints
  • Lack of the computational resources and staffing to analyze and interpret clinical data
• Market Opportunities
  • Continuous focus on new technology development novel targeted sequencing technologies
  • Increased support from government and private sector for large scale sequencing technology
• Market Challenges
  • Ethical and privacy concerns related to targeted sequencing data protection

Porter's Five Forces: A Strategic Tool for Navigating the Targeted Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Targeted Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Targeted Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Targeted Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Targeted Sequencing Market

A detailed market share analysis in the Targeted Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Targeted Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Targeted Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Targeted Sequencing Market

A strategic analysis of the Targeted Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Targeted Sequencing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., A-Alpha Bio, Inc., Agilent Technologies, Inc., Azenta Life Sciences, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., CD Genomics, DH Life Sciences, LLC, Element Biosciences, F. Hoffmann-La Roche Ltd., Illumina, Inc., LGC Limited, Macrogen, Inc., MGI Tech Co., Ltd., Oxford Nanopore Technologies PLC, Pacific Biosciences of California, Inc., Paragon Genomics, Inc., PerkinElmer, Inc., Psomagen, Inc., QIAGEN N.V., Singular Genomics Systems, Inc., Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Twist Bioscience Corporation.

Market Segmentation & Coverage

This research report categorizes the Targeted Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Consumables, Platforms, and Services.
• Based on Application, market is studied across Cardiovascular Diseases, Hereditary Diseases, Infectious Diseases, Neurological Disorders, Oncology, and Reproductive Health.
• Based on End-User, market is studied across Academic & Research Institutes, Clinical Laboratories, Contract Research Organization, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Extensive adoption of targeted sequencing technologies in clinical diagnostics due to rapid result time and higher accuracy
    • 5.1.1.2. Emerging adoption in the agriculture sector to analyze the genetic potential of plants
    • 5.1.1.3. Increased application of targeted sequencing for precision medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of the computational resources and staffing to analyze and interpret clinical data
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous focus on new technology development novel targeted sequencing technologies
    • 5.1.3.2. Increased support from government and private sector for large scale sequencing technology
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical and privacy concerns related to targeted sequencing data protection
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Targeted Sequencing Market, by Product Type

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Platforms
• 6.4. Services

7. Targeted Sequencing Market, by Application

• 7.1. Introduction
• 7.2. Cardiovascular Diseases
• 7.3. Hereditary Diseases
• 7.4. Infectious Diseases
• 7.5. Neurological Disorders
• 7.6. Oncology
• 7.7. Reproductive Health

8. Targeted Sequencing Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Clinical Laboratories
• 8.4. Contract Research Organization
• 8.5. Pharmaceutical & Biotechnology Companies

9. Americas Targeted Sequencing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Targeted Sequencing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Targeted Sequencing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 10x Genomics, Inc.
• 2. A-Alpha Bio, Inc.
• 3. Agilent Technologies, Inc.
• 4. Azenta Life Sciences
• 5. BGI Genomics Co., Ltd.
• 6. Bio-Rad Laboratories, Inc.
• 7. CD Genomics
• 8. DH Life Sciences, LLC
• 9. Element Biosciences
• 10. F. Hoffmann-La Roche Ltd.
• 11. Illumina, Inc.
• 12. LGC Limited
• 13. Macrogen, Inc.
• 14. MGI Tech Co., Ltd.
• 15. Oxford Nanopore Technologies PLC
• 16. Pacific Biosciences of California, Inc.
• 17. Paragon Genomics, Inc.
• 18. PerkinElmer, Inc.
• 19. Psomagen, Inc.
• 20. QIAGEN N.V.
• 21. Singular Genomics Systems, Inc.
• 22. Takara Bio Inc.
• 23. Tecan Trading AG
• 24. Thermo Fisher Scientific Inc.
• 25. Twist Bioscience Corporation